Alembic Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Alembic Pharmaceuticals Ltd reported a 12.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.8%.
• Its expenses for the quarter were up by 14.2% QoQ and 8.5% YoY.
• The net profit decreased 13.8% QoQ and increased 14.2% YoY.
• The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 7.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alembic Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and marketing of pharmaceutical products. The company's product portfolio includes a wide range of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). Alembic Pharmaceuticals operates in several therapeutic segments, including cardiovascular, anti-diabetic, respiratory, and gastrointestinal, among others. As a well-established entity in the pharmaceutical sector, Alembic Pharmaceuticals has a significant presence in both domestic and international markets. Recent developments in the company, such as expansions in manufacturing capacities or entry into new markets, are not detailed in the data provided.

Revenue

The company's total income for Q1FY26 stood at ₹1,717.22 crores, an increase from ₹1,520.58 crores in Q4FY25 and ₹1,563.83 crores in Q1FY25. This represents a quarter-over-quarter (QoQ) growth rate of 12.9% and a year-over-year (YoY) increase of 9.8%. The rise in total income could be attributed to various factors, including increased sales volume, pricing adjustments, or expansion into new markets. However, specific drivers for this growth are not available in the data. The consistent increase in revenue year-over-year highlights the company's ability to maintain its market position and expand its income streams.

Profitability

Alembic Pharmaceuticals reported a profit before tax of ₹190.56 crores in Q1FY26, up from ₹183.24 crores in Q4FY25 and ₹156.71 crores in Q1FY25, marking a QoQ increase of 4.0% and a YoY growth of 21.6%. The tax expenses for Q1FY26 were ₹36.48 crores, significantly higher than the ₹4.64 crores reported in Q4FY25 and ₹22.49 crores in Q1FY25, reflecting a substantial QoQ increase of 686.2% and a YoY rise of 62.2%. Despite the higher tax outgo, the company achieved a profit after tax of ₹153.63 crores for Q1FY26, though this was a decrease from ₹178.21 crores in Q4FY25 but an increase from ₹134.54 crores in Q1FY25. This resulted in a QoQ decline of 13.8% and a YoY growth of 14.2%. Earnings per share for Q1FY26 were ₹7.80, down from ₹9.10 in Q4FY25 but up from ₹6.80 in Q1FY25.

Operating Metrics

Total expenses for Q1FY26 were ₹1,526.66 crores, up from ₹1,337.34 crores in Q4FY25 and ₹1,407.12 crores in Q1FY25, indicating a QoQ increase of 14.2% and a YoY growth of 8.5%. The increase in expenses could involve higher costs associated with production, distribution, or other operational factors, but specific details are not provided in the data. The profit before tax margin, calculated as profit before tax divided by total income, was approximately 11.10% for Q1FY26, compared to 12.05% in Q4FY25 and 10.02% in Q1FY25. These operating metrics reveal fluctuations in the company's cost structure and profitability margins over the periods analyzed.